| Species |
Human |
| Protein Construction |
MOG/Myelin Oligodendrocyte Glycoprotein (Gly30-Gly154)_x000D_
Accession # Q16653 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
15.4 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 20-23 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Myelin oligodendrocyte glycoprotein (MOG) antibody disease is a rare autoimmune disorder with antibodies against the MOG predominantly involving the optic nerve and spinal cord leading to vision loss and paralysis. When MOG antibody disease involves the brain, the phenotype is similar to acute disseminated encephalomyelitis (ADEM). |
| Synonyms |
MOG; MGC26137; MOG Ig-AluB; MOGIG2; BTN6; BTNL11; NRCLP7 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
